These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23795914)

  • 21. p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011).
    Fischer S; Koeberle SC; Laufer SA
    Expert Opin Ther Pat; 2011 Dec; 21(12):1843-66. PubMed ID: 22082194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classical PKC isoforms in cancer.
    Martiny-Baron G; Fabbro D
    Pharmacol Res; 2007 Jun; 55(6):477-86. PubMed ID: 17548205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based optimization of PKCtheta inhibitors.
    Mosyak L; Xu Z; Joseph-McCarthy D; Brooijmans N; Somers W; Chaudhary D
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1027-31. PubMed ID: 17956269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PKCtheta: A potential therapeutic target for T-cell-mediated diseases.
    Chaudhary D; Kasaian M
    Curr Opin Investig Drugs; 2006 May; 7(5):432-7. PubMed ID: 16729719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical protein kinase Cι as a human oncogene and therapeutic target.
    Parker PJ; Justilien V; Riou P; Linch M; Fields AP
    Biochem Pharmacol; 2014 Mar; 88(1):1-11. PubMed ID: 24231509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).
    Marzaro G; Guiotto A; Chilin A
    Expert Opin Ther Pat; 2012 Mar; 22(3):223-52. PubMed ID: 22404097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pim kinase inhibitors: a survey of the patent literature.
    Morwick T
    Expert Opin Ther Pat; 2010 Feb; 20(2):193-212. PubMed ID: 20100002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.
    Cole DC; Asselin M; Brennan A; Czerwinski R; Ellingboe JW; Fitz L; Greco R; Huang X; Joseph-McCarthy D; Kelly MF; Kirisits M; Lee J; Li Y; Morgan P; Stock JR; Tsao DH; Wissner A; Yang X; Chaudhary D
    J Med Chem; 2008 Oct; 51(19):5958-63. PubMed ID: 18783200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Some different effect of PKC inhibitors on the acetylcholine, and endothelin-1-induced contractions of rat bronchial smooth muscle.
    Sakai H; Yamamoto M; Chiba Y; Misawa M
    Eur J Pharmacol; 2009 Sep; 618(1-3):58-62. PubMed ID: 19615994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct AMP-activated protein kinase activators: a review of evidence from the patent literature.
    Giordanetto F; Karis D
    Expert Opin Ther Pat; 2012 Dec; 22(12):1467-77. PubMed ID: 23136886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Competitive inhibitors and allosteric activators of protein kinase C isoenzymes: a personal account and progress report on transferring academic discoveries to the clinic.
    Budas GR; Koyanagi T; Churchill EN; Mochly-Rosen D
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1021-6. PubMed ID: 17956268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphoinositide 3-kinase α inhibitors: a patent review.
    Denny WA
    Expert Opin Ther Pat; 2013 Jul; 23(7):789-99. PubMed ID: 23488930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent patents concerning modulators of protein kinase C.
    Sanchez-Bautista S; Nicolas FE
    Recent Pat DNA Gene Seq; 2013 Apr; 7(1):74-81. PubMed ID: 23061527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein kinase C inhibitors alter neurotensin receptor binding and function in prostate cancer PC3 cells.
    Carraway RE; Hassan S; Dobner PR
    Regul Pept; 2008 Apr; 147(1-3):96-109. PubMed ID: 18313772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein kinase C βII in diabetic complications: survey of structural, biological and computational studies.
    Sobhia ME; Grewal BK; Bhat J; Rohit S; Punia V
    Expert Opin Ther Targets; 2012 Mar; 16(3):325-44. PubMed ID: 22404224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elucidating the role of protein kinase C in chronic lymphocytic leukaemia.
    Michie AM; Nakagawa R
    Hematol Oncol; 2006 Sep; 24(3):134-8. PubMed ID: 16841369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
    Uckun FM; Qazi S
    Expert Opin Ther Pat; 2010 Nov; 20(11):1457-70. PubMed ID: 20831363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Technology evaluation: ISIS-3521.
    Li K; Zhang J; Sirois P; Hu Y
    Curr Opin Mol Ther; 1999 Jun; 1(3):393-8. PubMed ID: 11713804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methods for studying oxidative regulation of protein kinase C.
    Gopalakrishna R; McNeill TH; Elhiani AA; Gundimeda U
    Methods Enzymol; 2013; 528():79-98. PubMed ID: 23849860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calpain inhibitors: a survey of compounds reported in the patent and scientific literature.
    Donkor IO
    Expert Opin Ther Pat; 2011 May; 21(5):601-36. PubMed ID: 21434837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.